Patients With Overweight or Obesity Show Significant Weight Loss in Phase 2 Survodutide Trial
After receiving 4.8 mg of survodutide weekly for 46 weeks, more than half of trial participants achieved weight loss of 15% or more.
After receiving 4.8 mg of survodutide weekly for 46 weeks, more than half of trial participants achieved weight loss of 15% or more.
Patients taking semaglutide for a year saw significant improvements in exercise capacity and lost 2.9% more body weight compared with patients taking placebo.
During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory…
Robert Gabbay, MD, PhD, discusses type 1 diabetes by addressing the distinct stages of the disease, risk factors, and current and emerging treatments.
Certain genes have been linked to significant weight reduction in obesity treatment; research boosts plaintiffs’ cases against Johnson & Johnson for their talc-based baby powder;…
Fatima Rodriguez, MD, MPH, from Stanford University, and Matthew DeCamp, MD, PhD, from the University of Colorado, joined Michael Howell, MD, MPH, of Google, on…
Patients with HIV who switched to a treatment regimen that included tenofovir alafenamide (TAF) showed improvement in serum markers for hepatic steatosis (HS) among other…
The FDA has approved tarlatamab (Imdelltra; Amgen), a novel bispecific T-cell engager, to treat patients with extensive-stage small cell lung cancer (SCLC).
Ronald D. Alvarez, MD, MBA, discusses challenges in implementing updated NCCN guidelines, such as coverage limitations imposed by payers.
A panel of experts provide an overview of gene therapy, review recently approved gene therapies for rare diseases such as hemophilia, spinal muscular atrophy, and…
Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, shares what women can do to prioritize their heart health during National Women’s Health Week and every…